ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,404 GBX | +0.47% |
|
+3.13% | +17.02% |
| 03:18pm | ASTRAZENECA : UBS reiterates advice after ASCO meeting | CF |
| 11:54am | ASTRAZENECA : Gets a Sell rating from UBS | ZD |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
06:00am
- Investor Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.9
USD
Average target price
172.1
USD
Spread / Average Target
+8.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.02% | 24TCr | |
| +42.65% | 75TCr | |
| +34.11% | 60TCr | |
| -6.07% | 36TCr | |
| +18.28% | 33TCr | |
| +4.76% | 28TCr | |
| +9.26% | 21TCr | |
| -4.21% | 21TCr | |
| +3.14% | 17TCr | |
| +7.43% | 16TCr |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca : Fire Claims Five at AstraZeneca's COVID-19 Vaccine Maker Serum Institute of India; Production to Continue
